Document 3063
 DOCN  M94A3063
 TI    Anti-p24 titer: a marker for AIDS in Cuban HIV seropositives.
 DT    9412
 AU    Benitez J; Rivero J; CIGB, Havana, Cuba.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):162 (abstract no. PB0076). Unique
       Identifier : AIDSLINE ICA10/94369512
 AB    OBJECTIVE: To evaluate the use of anti-p24 antibody titer as a marker
       for the prognosis of AIDS in Cuban HIV-1 seropositives. METHODS: An
       ELISA for anti-p24 titration, based on recombinant HIV-1 p24, which uses
       a protein-A-peroxidase conjugate was used. Serum samples were 1:2
       serially diluted from 1:20 to 1:2560. Both the titer and the slope of
       the dilution curve were calculated. Anti-p24 antibody titers were
       quantified for 852 samples from 234 HIV infected individuals
       representative of all the stages of the infection, and in the
       longitudinal study, serum samples from 135 patients were sequentially
       evaluated for 36 months. RESULTS AND CONCLUSIONS: Titers lower than
       1:160 were obtained for 84.8% of the AIDS patients, and statistical
       significant differences were found between AIDS cases and group II (p <
       0.00006) and group III cases (p < 0.00003). In 36 group II or III
       patients, a decrease of the anti-p24 titer was observed prior to or in
       correlation with disease progression. We conclude that (1) p24 low
       responders are at higher risk for AIDS than high responders. (2)
       Anti-p24 titer is an accurate marker for the progression to AIDS, and
       represent an economical alternative for the follow up of HIV
       seropositives in developing countries.
 DE    Acquired Immunodeficiency Syndrome/CLASSIFICATION/*DIAGNOSIS/
       IMMUNOLOGY  AIDS Serodiagnosis/ECONOMICS  Cost-Benefit Analysis  Cuba
       *Developing Countries  Enzyme-Linked Immunosorbent Assay/ECONOMICS
       Follow-Up Studies  Human  HIV Antibodies/*BLOOD  HIV Core Protein
       p24/*IMMUNOLOGY  HIV Seropositivity/CLASSIFICATION/*DIAGNOSIS/IMMUNOLOGY
       HIV-1/*IMMUNOLOGY  Longitudinal Studies  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).